WO1998016523A9 - Inhibiteurs competitifs du facteur xa - Google Patents
Inhibiteurs competitifs du facteur xaInfo
- Publication number
- WO1998016523A9 WO1998016523A9 PCT/US1997/018291 US9718291W WO9816523A9 WO 1998016523 A9 WO1998016523 A9 WO 1998016523A9 US 9718291 W US9718291 W US 9718291W WO 9816523 A9 WO9816523 A9 WO 9816523A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- alkyl
- aryl
- integer
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims description 47
- 108010074860 Factor Xa Proteins 0.000 title abstract description 36
- 239000003112 inhibitor Substances 0.000 title description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 150
- 125000003118 aryl group Chemical group 0.000 claims description 68
- 229910052739 hydrogen Inorganic materials 0.000 claims description 65
- 125000005842 heteroatoms Chemical group 0.000 claims description 28
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- -1 C5.6cycloalkyl Chemical group 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 239000003146 anticoagulant agent Substances 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 17
- 238000005755 formation reaction Methods 0.000 claims description 14
- 230000015271 coagulation Effects 0.000 claims description 13
- 238000005345 coagulation Methods 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 9
- 208000010125 Myocardial Infarction Diseases 0.000 claims description 7
- 208000007536 Thrombosis Diseases 0.000 claims description 7
- 206010047249 Venous thrombosis Diseases 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 7
- 230000003287 optical Effects 0.000 claims description 7
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 5
- 210000004351 Coronary Vessels Anatomy 0.000 claims description 4
- 206010038563 Reocclusion Diseases 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- 206010002383 Angina pectoris Diseases 0.000 claims description 3
- 206010002388 Angina unstable Diseases 0.000 claims description 3
- 206010009802 Coagulopathy Diseases 0.000 claims description 3
- 208000009190 Disseminated Intravascular Coagulation Diseases 0.000 claims description 3
- 206010014498 Embolic stroke Diseases 0.000 claims description 3
- 206010040070 Septic shock Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 206010043647 Thrombotic stroke Diseases 0.000 claims description 3
- 206010044390 Transient ischaemic attack Diseases 0.000 claims description 3
- 208000007814 Unstable Angina Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 200000000008 restenosis Diseases 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 230000002537 thrombolytic Effects 0.000 claims description 3
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 3
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 206010062599 Arterial occlusive disease Diseases 0.000 claims description 2
- 206010053567 Coagulopathy Diseases 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 238000007887 coronary angioplasty Methods 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 230000002093 peripheral Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 37
- 239000011780 sodium chloride Substances 0.000 abstract description 32
- 150000003839 salts Chemical class 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 14
- 238000000338 in vitro Methods 0.000 abstract description 5
- 201000007368 coagulation protein disease Diseases 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 24
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 description 21
- 108090000190 Thrombin Proteins 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 229960004072 thrombin Drugs 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 230000002429 anti-coagulation Effects 0.000 description 11
- 125000004432 carbon atoms Chemical group C* 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 238000004166 bioassay Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000000651 prodrug Chemical class 0.000 description 10
- 229940002612 prodrugs Drugs 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- SPUGSTAFPSRNFE-UHFFFAOYSA-N N-(4-hydroxyphenyl)-2-phenoxyacetamide Chemical compound C1=CC(O)=CC=C1NC(=O)COC1=CC=CC=C1 SPUGSTAFPSRNFE-UHFFFAOYSA-N 0.000 description 9
- 230000003389 potentiating Effects 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 230000001808 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 229910001868 water Inorganic materials 0.000 description 8
- 102100008880 TFPI Human genes 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 230000002785 anti-thrombosis Effects 0.000 description 7
- 230000023555 blood coagulation Effects 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- 108010014806 prothrombinase complex Proteins 0.000 description 7
- 210000004369 Blood Anatomy 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 101710034269 TFPI Proteins 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 230000023597 hemostasis Effects 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000001225 therapeutic Effects 0.000 description 6
- 229940088598 Enzyme Drugs 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229910052681 coesite Inorganic materials 0.000 description 5
- 229910052906 cristobalite Inorganic materials 0.000 description 5
- 229940079593 drugs Drugs 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 229910052904 quartz Inorganic materials 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 229910052682 stishovite Inorganic materials 0.000 description 5
- 229910052905 tridymite Inorganic materials 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YHGZEZKUEMFPNZ-UHFFFAOYSA-N 3-hydroxy-5,5-dimethyl-4-phenyl-2-propanoylcyclohex-2-en-1-one Chemical compound CC1(C)CC(=O)C(C(=O)CC)=C(O)C1C1=CC=CC=C1 YHGZEZKUEMFPNZ-UHFFFAOYSA-N 0.000 description 4
- ZWSWPQHKDLDIDL-UHFFFAOYSA-N 7-(2-hydroxypropan-2-yl)-1,4a-dimethyl-3,4,5,6,7,8-hexahydronaphthalen-2-one Chemical compound C1C(C(C)(C)O)CCC2(C)CCC(=O)C(C)=C21 ZWSWPQHKDLDIDL-UHFFFAOYSA-N 0.000 description 4
- 108091005771 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000003527 fibrinolytic agent Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003000 nontoxic Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- VJZRBVVLWLEXBB-VROPFNGYSA-N (2S)-N-[(2S)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]-1-[2-[(4-methylphenyl)sulfonylamino]acetyl]pyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1S(=O)(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)CCC1 VJZRBVVLWLEXBB-VROPFNGYSA-N 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N Depacane Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 3
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 3
- 102100015239 F2 Human genes 0.000 description 3
- 229950003499 FIBRIN Drugs 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- 241000237654 Haementeria ghilianii Species 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 229940039716 Prothrombin Drugs 0.000 description 3
- 108010094028 Prothrombin Proteins 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 101700028178 antA Proteins 0.000 description 3
- 102000004965 antibodies Human genes 0.000 description 3
- 108090001123 antibodies Proteins 0.000 description 3
- 230000000890 antigenic Effects 0.000 description 3
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 108010018472 chromozym TH Proteins 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 230000002255 enzymatic Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 230000002489 hematologic Effects 0.000 description 3
- 229940020899 hematological Enzymes Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012453 solvate Chemical class 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 239000003868 thrombin inhibitor Substances 0.000 description 3
- 229960000103 thrombolytic agents Drugs 0.000 description 3
- 108010065972 tick anticoagulant peptide Proteins 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N Anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000001772 Blood Platelets Anatomy 0.000 description 2
- 210000004204 Blood Vessels Anatomy 0.000 description 2
- 229940019700 Blood coagulation factors Drugs 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N C[N+](C)(C)CCO Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 Choline Drugs 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 102000033147 ERVK-25 Human genes 0.000 description 2
- 108010074105 Factor Va Proteins 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229940093915 Gynecological Organic acids Drugs 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102000035443 Peptidases Human genes 0.000 description 2
- 108010001014 Plasminogen Activators Proteins 0.000 description 2
- 102000001938 Plasminogen Activators Human genes 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 102000017975 Protein C Human genes 0.000 description 2
- 229960000856 Protein C Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000003296 Saliva Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N Theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Trimethylglycine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000003197 catalytic Effects 0.000 description 2
- 230000024881 catalytic activity Effects 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000010192 crystallographic characterization Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- 230000002439 hemostatic Effects 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 108060005018 mobB Proteins 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002947 procoagulant Effects 0.000 description 2
- 239000003805 procoagulant Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001732 thrombotic Effects 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- VKMGSWIFEHZQRS-NSHDSACASA-N (1R)-1-(3,4-dichlorophenyl)-2-(propan-2-ylamino)ethanol Chemical compound CC(C)NC[C@H](O)C1=CC=C(Cl)C(Cl)=C1 VKMGSWIFEHZQRS-NSHDSACASA-N 0.000 description 1
- WBIIPXYJAMICNU-AWEZNQCLSA-N (2S)-5-[amino-[(4-methylphenyl)sulfonylamino]methylidene]azaniumyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound CC1=CC=C(S(=O)(=O)NC(N)=NCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C=C1 WBIIPXYJAMICNU-AWEZNQCLSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- XWZDPNBLQJCKNC-UHFFFAOYSA-N 3-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]propanoic acid Chemical compound CC(C)(C)OC(=O)N1CCC(CCC(O)=O)CC1 XWZDPNBLQJCKNC-UHFFFAOYSA-N 0.000 description 1
- XRZWVSXEDRYQGC-UHFFFAOYSA-N 4-cyclohexylpyrrolidin-1-ium-2-carboxylate Chemical compound C1NC(C(=O)O)CC1C1CCCCC1 XRZWVSXEDRYQGC-UHFFFAOYSA-N 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005054 ACEPROMAZINE Drugs 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N Acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- MGEVGECQZUIPSV-UHFFFAOYSA-N BOP reagent Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 MGEVGECQZUIPSV-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940039227 DIAGNOSTIC AGENTS Drugs 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 241001505404 Deinagkistrodon acutus Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N Diethylethanolamine Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229940012017 Ethylenediamine Drugs 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 210000003191 Femoral Vein Anatomy 0.000 description 1
- 229940012952 Fibrinogen Drugs 0.000 description 1
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- 229960002442 Glucosamine Drugs 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N Glyoxylic acid Natural products OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N HF Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 241000237655 Haementeria Species 0.000 description 1
- 241000237664 Haementeria officinalis Species 0.000 description 1
- 206010019016 Haemorrhagic stroke Diseases 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 229960002885 Histidine Drugs 0.000 description 1
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 1
- 102000018358 Immunoglobulins Human genes 0.000 description 1
- 108060003951 Immunoglobulins Proteins 0.000 description 1
- IQZZFVDIZRWADY-UHFFFAOYSA-N Isocoumarin Chemical compound C1=CC=C2C(=O)OC=CC2=C1 IQZZFVDIZRWADY-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MQQNFDZXWVTQEH-UHFFFAOYSA-N Nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 description 1
- 229940074730 OPHTHAMOLOGIC DIAGNOSTIC AGENTS Drugs 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 description 1
- 229940012957 Plasmin Drugs 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 210000003492 Pulmonary Veins Anatomy 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 210000003079 Salivary Glands Anatomy 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 1
- 229960005202 Streptokinase Drugs 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100008471 THBD Human genes 0.000 description 1
- 229960004559 Theobromine Drugs 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 229960005356 Urokinase Drugs 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 231100000611 Venom Toxicity 0.000 description 1
- 210000001048 Venoms Anatomy 0.000 description 1
- 229940088594 Vitamin Drugs 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 229960005080 Warfarin Drugs 0.000 description 1
- 101700058870 XI Proteins 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N Xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 Xylazine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000003187 abdominal Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000005024 alkenyl aryl group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005741 alkyl alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000003024 amidolytic Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229940042397 direct acting antivirals Cyclic amines Drugs 0.000 description 1
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 108060000102 eco Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000002319 fibrinogen receptor antagonist Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000003480 fibrinolytic Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 230000002008 hemorrhagic Effects 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- QUFUZPOMGMZNNL-UHFFFAOYSA-N lithium;2H-1,3-thiazol-2-ide Chemical compound [Li+].C1=CS[C-]=N1 QUFUZPOMGMZNNL-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WXEHBUMAEPOYKP-UHFFFAOYSA-N methylsulfanylethane Chemical compound CCSC WXEHBUMAEPOYKP-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229950009865 nafamostat Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000004928 piperidonyl group Chemical group 0.000 description 1
- 230000000896 plasminic Effects 0.000 description 1
- 200000000002 platelet activation Diseases 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 150000004672 propanoic acids Chemical class 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 230000003331 prothrombotic Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N stearylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 231100000803 sterility Toxicity 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000002885 thrombogenetic Effects 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Definitions
- This invention relates to novel heterocyclic compounds which are potent and highly selective inhibitors of factor Xa or factor Xa when assembled in the prothrombinase complex. These compounds show selectivity for factor Xa versus other proteases of the coagulation (e.g. thrombin, fVIIa, flXa) or the fibrinolytic cascades (e.g. plasminogen activators, plasmin).
- Blood coagulation protects mammalian species when the integrity of the blood vessel wall is damaged and uncontrolled loss of blood threatens survival. Coagulation, resulting in the clotting of blood is an important component of hemostasis. Under normal hemostatic circumstances, there is maintained an acute balance of clot formation and clot removal (fibrinolysis).
- the blood coagulation cascade involves the conversion of a variety of inactive enzymes (zymogens) into active enzymes which ultimately convert the soluble plasma protein fibrinogen into an insoluble matrix of highly cross-linked fibrin.
- thrombin A key enzyme in the coagulation cascade as well as in hemostasis, is thrombin.
- Thrombin is intimately involved in the process of thrombus formation, but under normal circumstances can also play an anticoagulant role in hemostasis through its ability to convert protein C into activated protein C in a thrombomodulin-dependent manner.
- Thrombin plays a central role in thrombosis through its ability to catalyze the penultimate conversion of fibrinogen into fibrin and through its potent platelet activation activity.
- thrombin activity has been the focus of a variety of recent anticoagulant strategies as reviewed by Claeson "Synthetic Peptides and Peptidomimetics as Substrates and Inhibitors of Thrombin and Other Proteases in the Blood Coagulation System", Blood Coag. Fibrinol. 5:411-436 (1994).
- the major classes of anticoagulants currently used in the clinic directly or indirectly affect thrombin (i.e. heparins, low-molecular weight heparins and coumarins).
- thrombin i.e. heparins, low-molecular weight heparins and coumarins.
- Thrombin is generated at the convergence of the intrinsic and extrinsic coagulation pathways by the prothrombinase complex.
- the prothrombinase complex is formed when activated Factor X (factor Xa) and its non-enzymatic cofactor, factor Va assemble on phospholipid surfaces in a Ca" 2 - dependent fashion as reviewed by Mann, et al, "Surface-Dependent Reactions of the Vitamin -Dependent Enzymes", Blood 76:1-16 (1990).
- Factor X Factor Xa
- factor Va Factor Xa
- the prothrombinase complex converts the zymogen prothrombin into the active procoagulant thrombin.
- prothrombinase complex The location of the prothrombinase complex at the convergence of the intrinsic and extrinsic coagulation pathways, and the significant amplification of thrombin generation (393,000-fold over uncomplexed factor Xa) mediated by the complex at a limited number of targeted catalytic units present at vascular lesion sites, suggests that inhibition of thrombin generation is an ideal method to block uncontrolled procoagulant activity.
- factor Xa appears to have a single physiologic substrate, namely prothrombin.
- Plasma contains an endogenous inhibitor of both the factor Vila-tissue factor (TF) complex and factor Xa called tissue factor pathway inhibitor (TFPI).
- TFPI is a unitz- type protease inhibitor with three tandem Kunitz domains.
- TFPI inhibits the TF/fVIIa complex in a two-step mechanism which includes the initial interaction of the second Kunitz domain of TFPI with the active site of factor Xa, thereby inhibiting the proteolytic activity of factor Xa.
- the second step involves the inhibition of the TF/fVIIa complex by formation of a quaternary complex TF/fVIIa TFPI/fXa as described by Girard, et al , "Functional Significance of the Kunitz-type Inhibitory Domains of Lipoprotein-associated Coagulation Inhibitor", Nature 338:518-520 (1989).
- Tick Anticoagulant Peptide is a Novel Inhibitor of Blood Coagulation Factor Xa", Science 248:593-596 (1990).
- WO 96/18644 to Tamura, et al describes aromatic heterocyclic thrombin inhibitors.
- WO 95/35313 to Semple, et al. pertains to 3-amino-2-oxo-l-piperidineacetic derivative thrombin inhibitors.
- EP 0.512.831 and US Patent No. 5,281,585, both to Duggan, et al.. describe fibrinogen receptor antagonists.
- the present invention relates to novel peptide and peptide mimetic analogs, their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives.
- the present invention includes pharmaceutical compositions comprising a pharmaceutically effective amount of the compounds of this invention and a pharmaceutically acceptable carrier. These compositions are useful as potent and specific inhibitors of blood coagulation in mammals.
- the invention relates to methods of using these inhibitors as therapeutic agents for disease states in mammals which have disorders of coagulation such as in the treatment or prevention of unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, thrombotic stroke, embolic stroke, disseminated intravascular coagulation including the treatment of septic shock, deep venous thrombosis in the prevention of pulmonary embolism or the treatment of reocclusion or restenosis of reperfused coronary arteries.
- These compositions may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents.
- the present invention provides compounds of general formula I:
- R 1 is H, C,. 6 alkyl or C ⁇ . 3 alkylaryl
- R 2 is H, C,. 6 alkyl, C 3 . 6 cycloalkyl, C,. 3 alkylaryl, C l . 3 alkyl-C 3 . 8 cycloalkyl or aryl and R 3 is H, C ⁇ alkyl, or R 2 and R 3 are taken together to form a carbocyclic ring;
- m is an integer from 0-3;
- n is an integer from 0-6;
- p is an integer from 0-4;
- s is an integer from 0-2;
- q is an integer from 0-2;
- A is selected from the group consisting of: a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S;
- R 4 ; -NR 4 R 5 is selected from the group consisting of:
- R 4 , R 3 , R 16 and R 17 are independently selected from the group consisting of H. -OH, C
- R 16 or R 17 to form a 5-6 membered ring and R 19 is selected from the group consisting of H, -OH, Chalky 1, aryl and or can be taken together with R 17 to form a 5-6 membered ring;
- W is a direct link, C ⁇ . 6 alkyl, C 3-8 cycloalkyl, C ⁇ -6 alkenyl, C ⁇ . 6 alkenylaryl, aryl, or a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S;
- D is a direct link, -CO-, -SO 2 -, -CH 2 -, -O-CO-, -NR 15 SO 2 - or -NR l 5 -CO-, where R 15 is selected from the group consisting of H, -OH, C t . 6 alkyl. aryl and C l . 4 al ylaryl;
- K. is selected from the group consisting of a direct link, C 3 . 8 cycloalkyl, aryl. or a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, 0 and S;
- E is selected from the group consisting of R 26 , -NR 26 R 27 ,
- R 26 , R 27 , R 28 and R 29 are independently selected from the group consisting of H, -OH, C
- R 30 is selected from the group consisting of H, C ⁇ . 6 alkyl, aryl and C 1- alkylaryl, or can be taken together with R 28 or R 29 to form a 5-6 membered ring;
- R 31 is selected from the group consisting of H. C 6 alkyl, aryl and C ⁇ _ ⁇ alkylaryl, or can be taken together with R 29 to form a 5-6 membered ring; with the proviso that when E is R 26 , then K must contain at least one N atom;
- Y is selected from the group consisting of H,
- R 13 and R 14 are independently selected from the group consisting of H, C,. 3 alkyl and aryl; and G is -COOR 20 , -CONR 20 R 2 ⁇ -CF 3 , -CF 2 CF 3 or a group having the formula:
- R- is selected from the group consisting of H, C,. 6 alkyl, C 2 . 6 alkenyl, C 0.6 alkylaryl C 2 -6alkenylaryl, C 0 . 6 alkylheterocyclo, C 2 . 6 alkenylheterocyclo, -CF 3 and -CF 2 CF 3 ;
- U is -0-, -S-. -N- or -N(H)-;
- V is -0-, -S-, -N- or -N(H)-; with the proviso that at least one of U or V is -N- or -N(H)-;
- J is -S-, -SO-. -SO , -O- or -NR 6 -, where R 6 is H, C,. 6 alkyl or benzyl;
- L is selected from the group consisting of:
- R 9 and R 10 are independently selected from the group consisting of H, C l-6 alkyl, aryl, C ⁇ alkylaryl, -COOR 1 1 ,
- R 9 and R 10 are independently selected from the group consisting of H, C ⁇ . 6 alkyl, aryl, C ⁇ -6 alkylaryl, halogen, -N0 2 , -NR"R 12 .
- R 1 ' and R 12 are independently selected from the group consisting of
- alkyl refers to saturated aliphatic groups including straight-chain, branched-chain, cyclic groups, and combinations thereof, having the number of carbon atoms specified, or if no number is specified, having up to 12 carbon atoms.
- cycloalkyl refers to a mono-, bi-. or tricyclic aliphatic ring having 3 to 12 carbon atoms, preferably 3 to 7 carbon atoms.
- alkenyl refers to unsaturated aliphatic groups including straight-chain, branched-chain, cyclic groups, and combinations thereof, having at least one double bond and having the number of carbon atoms specified.
- aryl refers to an unsubstituted or substituted aromatic ring(s), substituted with one, two or three substituents such as, by way of example and not limitation, C 6 alkoxy, C, .6 alkyl, C, .6 alkylamino, hydroxy, halogen, cyano (-CN), hydroxyl, mercapto, nitro (-NO 2 ), thioalkoxy, carboxaldehyde, carboxyl, carboalkoxy, carboxamide, -NR'R", -NR'COR", -OR, -OCOR, -COOR, -CONR'R", -CF 3 , -SO 2 NR'R" and
- aryl C ⁇ -6 alkylaryl (where the R groups can be H, C,. 6 alkyl, C ⁇ alkylaryl and aryl), including but not limited to carbocyclic aryl, heterocyclic aryl. biaryl and triaryl groups and the like, all of which may be optionally substituted.
- Preferred aryl groups include phenyl, halophenyl, C 1-6 alkylphenyl, naphthyl, biphenyl, phenanthrenyl, naphthacenyl, and aromatic heterocyclics or heteroaryls, the latter of which is an aryl group containing one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
- Aryl groups preferably have 5-14 carbon atoms making up the ring(s) structure, while heteroaryls preferably have 1-4 heteroatoms, with the remaining 4-10 atoms being carbon atoms.
- heterocyclo and “hetero cyclic ring system” as used herein refer to any saturated or unsaturated mono- or bicyclic ring system, containing from one to four heteroatoms, selected from the group consisting of nitrogen, oxygen and sulfur.
- a typical heterocyclic ring system will have five to ten members, 1-4 of which are heteroatoms.
- Typical examples of monocyclic ring systems include piperidinyl, pyrrolidinyl, pyridinyl, piperidonyl, pyrrolidonyl and thiazolyl, while examples of bicyclic ring systems include benzimidazolyl, benzothiazolyl and benzoxazolyl, all of which may be substituted.
- carrier ring refers to any saturated or unsaturated ring containing from three to six carbon atoms.
- alkylaryl and alkenylaryl refer to an alkyl group or alkenyl group, respectively, having the number of carbon atoms designated, appended to one, two, or three aryl groups.
- benzyl refers to -CH 2 -C 6 H 5 .
- alkoxy refers to an alkyl linked to an oxygen atom, such as methoxy, ethoxy, and so forth.
- halogen refers to Cl, Br, F or I substi ents.
- direct link refers to a bond directly linking the substiments on each side of the direct link. When two adjacent substiments are defined as each being a “direct link”, it is considered to be a single bond.
- Two substiments are "taken together to form a 5-6 membered ring” means that an ethylene or a propylene bridge, respectively, is formed between the two substiments.
- pharmaceutically acceptable salts includes salts of compounds derived from the combination of a compound and an organic or inorganic acid. These compounds are useful in both free base and salt form. In practice, the use of the salt form amounts to use of the base form; both acid and base addition salts are within the scope of the present invention.
- “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
- inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like
- organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid
- “Pharmaceutically acceptable base addition salts” include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum bases, and the like. Particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts.
- Salts derived from pharmaceutically acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperizine, piperidine, N-ethylpiperidine, polyamine resins and the like.
- Particularly preferred organic nontoxic bases are isopropylamine, diethylamine, ethanolamine, trimethamine, dicyclohexylamine, choline, and caffeine.
- Bio property for the purposes herein means an in vivo effector or antigenic function or activity that is directly or indirectly performed by a compound of this invention. Effector functions include receptor or ligand binding, any enzyme activity or enzyme modulatory activity, any carrier binding activity, any hormonal activity, any activity in promoting or inhibiting adhesion of cells to an extracellular matrix or cell surface molecules, or any structural role. Antigenic functions include possession of an epitope or antigenic site that is capable of reacting with antibodies raised against it. The biological properties of the compounds of the present invention can be readily characterized by the methods described in Examples 14 and 15 and by such other methods as are well known in the art.
- Boc refers to t-butoxycarbonyl
- BOP refers to benzotriazol-l-yloxy-tris-(dimethylamino) phosphonium hexafluorophosphate.
- CBZ refers to benzyloxycarbonyl.
- DIEA diisopropylethylamine
- DMF N,N-dimethylformamide
- Et 2 O diethyl ether
- EtOAc ethyl acetate
- HF hydrogen fluoride
- HOAc acetic acid
- Mel refers to methyl iodide.
- MeOH refers to methanol.
- MeSEt refers to methyl ethyl sulfide.
- TFA trifluoroacetic acid.
- THF tetrahydrofuran.
- Tos refers top-toluenesulfonyl.
- carbon atoms bonded to four non-identical substiments are asymmetric. Accordingly, the compounds may exist as diastereoisomers, enantiomers or mixtures thereof.
- the syntheses described herein may employ racemates, enantiomers or diastereomers as starting materials or intermediates. Diastereomeric products resulting from such syntheses may be separated by chromatographic or crystallization methods, or by other methods known in the art.
- enantiomeric product mixtures may be separated using the same techniques or by other methods known in the art.
- Each of the asymmetric carbon atoms when present in the compounds of this invention, may be in one of two configurations (R or S) and both are within the scope of the present invention.
- the final products may. in some cases, contain a small amount of diastereomeric or enantiomeric products, however these products do not affect their therapeutic or diagnostic application.
- This replacement can be made by methods known in the art.
- This invention relates to a new class of peptide derivatives selected from those of general formula I which are potent and specific inhibitors of Xa, their pharmaceutically acceptable compositions thereof, and the methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis:
- R 1 is H, C ! . 6 alkyl or C,. 3 alkylaryl;
- R 2 is H, C,. 6 alkyl, C- ⁇ cycloalkyl, C,. 3 alkylaryl, C,. 3 alkyl-C 3-8 cycloalkyl or aryl and R 3 is H, C 1-6 alkyl, or R 2 and R 3 are taken together to form a carbocyclic ring;
- m is an integer from 0-3;
- n is an integer from 0-6;
- p is an integer from 0-4;
- s is an integer from 0-2;
- q is an integer from 0-2;
- A is selected from the group consisting of: a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S; R 4 ; -NR 4 R 5 ;
- R 4 , R ⁇ R 16 and R 17 are independently selected from the group consisting of H,
- R 18 is selected from the group consisting of H,
- R 19 is selected from the group consisting of H, -OH, C ⁇ alkyl. aryl and or can be taken together with R 17 to form a 5-6 membered ring; W is a direct link, C
- D is a direct link, -CO-, -SO , -CH 2 -, -O-CO-, -NR 15 SO 2 - or -NR 15 -CO-.
- R 15 is selected from the group consisting of H, -OH, C ⁇ alkyl, aryl and C alkylaryl; is selected from the group consisting of a direct link, C 3 . 8 cycloalkyl, aryl.
- E is selected from the group consisting of R 26 , -NR 26 R 27 , where R 26 , R 27 , R 28 and R 29 are independently selected from the group consisting of H, -OH, C
- R 31 is selected from the group consisting of H, C ⁇ alkyl, aryl and C 1-4 alkylaryl, or can be taken together with R 29 to form a 5-6 membered ring; with the proviso that when E is R 26 , then K. must contain at least one N atom; Y is selected from the group consisting of H,
- R 13 and R 14 are independently selected from the group consisting of H. C l-3 alkyl and aryl; and G is -COOR 20 , -CONR 20 R 21 , -CF 3 , -CF 2 CF 3 or a group having the formula:
- R 22 is selected from the group consisting of H, C,. 6 alkyl, C 2 . 6 alkenyl, C 0 . 6 alkylaryl, C 2 . 6 alkenylaryl, C 0 - 6 alkylheterocyclo, C 2 . 6 alkenylheterocyclo, -CF 3 and -CF 2 CF 3 ;
- U is -O-, -S-, -N- or -N(H ;
- V is -O-, -S-, -N- or -N(H)-; with the proviso that at least one of U or V is -N- or -N(H>; J is -S-, -SO-, -SO 2 -, -O- or -NR 6 -, where R 6 is H, C,. 6 alkyl or benzyl; and L is selected from the group consisting of:
- R 9 and R 10 are independently selected from the group consisting of H, C t .
- R l substiments are H and C ⁇ -6 alkyl; more preferably H.
- Preferred R 2 substiments are H and C 1-6 alkyl; more preferably H.
- R 3 is preferably H.
- the integer “m” is preferably from 0-1; more preferably 0.
- the integer “n” is preferably from 1-4.
- the integer “p” is preferably 3.
- the integer “s” is preferably 0.
- the integer “q” is preferably from 0-1.
- Preferred "A" substiments are R 4 , -NR 4 R 5 , 7
- R 4 is preferably H, -OH or C,. 6 alkyl; more preferably H, -OH or methyl.
- R 3 is preferably H, -OH or C ( . 6 alkyl; more preferably H, -OH or methyl.
- Preferred "W" substiments are C alkyl, C 5-6 cycloalkyl, aryl, or a five to ten membered heterocyclic ring system containing at least one N heteroatom; more preferably
- Preferred "D" substiments are -CO-, -SO 2 - and -CH 2 -; more preferably -CO- and -SO2-. is preferably a direct link.
- R 26 R 27 , R 28 , R 29 , R 30 and R 31 are independently selected from the group consisting of H and C ⁇ . 6 alkyl, more preferably H and methyl.
- Preferred " Y" substiments are:
- R 13 is preferably H.
- R 14 is preferably H.
- the "G" substi ent is preferably a group having the formula:
- the "J" substiment is preferably -S-, -O- or -NR 6 -.
- R 6 is preferably H.
- the "L” substiment is preferably:
- R 7 is preferably H.
- R 8 is preferably H.
- R 9 is preferably H, -O-R 11 , -COOR 11 , -CONR ⁇ R 12 or -CF 3 ; more preferably H.
- R 10 is preferably H, -O-R 11 , -COOR 11 , -CONR u R 12 or -CF 3 ; more preferably H.
- R" is preferably H.
- R 12 is preferably H.
- J and L are as defined above. This is also illustrated as a preferred group of compounds defined by the general structural formula II as: wherein: m is an integer from 0-3; n is an integer from 0-6; q is an integer from 0-2;
- A is selected from the group consisting of R 4 , -NR 4 R D ;
- R 4 , R ⁇ R 16 , R 17 , R 18 and R 19 are independently selected from the group consisting of H, -OH and C, ⁇ alkyl.
- W is C 1-6 alkyl, C 3-8 cycloalkyl, C
- L is selected from the group consisting of: a C 6 .[o heterocyclic ring system substituted by R 9 and R 10 and containing 1-4 heteroatoms selected from N, S and O; where r is an integer from 0-1 ; R 7 and R 8 are independently selected from the group consisting of H, C ⁇ . 6 alkyl, aryl, C ⁇ alkylaryl, -COOR", -CONR"R 12 , -CN and -CF 3 ; R 9 and R 10 are independently selected from the group consisting of H, C
- A is selected from the group consisting of R 4 , -NR 4 R 5 ;
- R 4 , R 5 , R 18 and R 19 are independently selected from the group consisting of H, -OH and C
- W is C,. 6 alkyl, C3.gcycl0a.kyl, C ⁇ . 6 alkenyl, aryl, or a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S; with the proviso that when A is R 4 , then W must contain at least one N atom;
- D is -CO- or -SO 2 -; and all optical isomers thereof.
- This invention also encompasses all pharmaceutically acceptable isomers, salts, hydrates and solvates of the compounds of formulas I, II and III.
- the compounds of formulas I, II and III can exist in various isomeric and tautomeric forms, and all such forms are meant to be included in the invention, along with pharmaceutically acceptable salts, hydrates and solvates of such isomers and tautomers.
- the compounds of this invention may be isolated as the free acid or base or converted to salts of various inorganic and organic acids and bases. Such salts are within the scope of this invention. Non-toxic and physiologically compatible salts are particularly useful although other less desirable salts may have use in the processes of isolation and purification.
- the free acid or free base form of a compound of one of the formulas above can be reacted with one or more molar equivalents of the desired acid or base in a solvent or solvent mixture in which the salt is insoluble, or in a solvent like water after which the solvent is removed by evaporation, distillation of freeze drying.
- the free acid or base form of the product may be passed over an ion exchange resin to form the desired salt or one salt form of the product may be converted to another using the same general process.
- prodrug refers to a pharmacologically inactive derivative of a parent drug molecule that requires biotransformation, either spontaneous or enzymatic, within the organism to release the active drug.
- Prodrugs are variations or derivatives of the compounds of this invention which have groups cleavable under metabolic conditions. Prodrugs become the compounds of the invention which are pharmaceutically active in vivo, when they undergo solvolysis under physiological conditions or undergo enzymatic degradation. Prodrug compounds of this invention may be called single, double, triple etc., depending on the number of biotransformation steps required to release the active drug within the organism, and indicating the number of functionalities present in a precursor-type form.
- Prodrug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985 and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academic Press, San Diego,
- Prodrugs commonly known in the art include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acids with a suitable alcohol, or amides prepared by reaction of the parent acid compound with an amine, or basic groups reacted to form an acylated base derivative.
- the prodrug derivatives of this invention may be combined with other features herein taught to enhance bioavailability.
- the compounds of this invention find utility as therapeutic agents for disease states in mammals which have disorders of coagulation such as in the treatment or prevention of unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, thrombotic stroke, embolic stroke, disseminated intravascular coagulation including the treatment of septic shock, deep venous thrombosis in the prevention of pulmonary embolism or the treatment of reocclusion or restenosis of reperfused coronary arteries. Further, these compounds are useful for the treatment or prophylaxis of those diseases which involve the production and/or action of factor Xa/prothrombinase complex.
- thrombotic and prothrombotic states in which the coagulation cascade is activated which include but are not limited to, deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, thromboembolic complications of surgery and peripheral arterial occlusion.
- a method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprises administering to the mammal a therapeutically effective amount of a compound of this invention.
- diseases treatable or preventable by the administration of compounds of this invention include, without limitation, occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty, thrombus formation in the venous vasculature, disseminated intravascular coagulopathy, a condition wherein there is rapid consumption of coagulation factors and systemic coagulation which results in the formation of life-threatening thrombi occurring throughout the microvasculature leading to widespread organ failure, hemorrhagic stroke, renal dialysis, blood oxygenation, and cardiac catheterization.
- the compounds of the invention also find utility in a method for inhibiting the coagulation biological samples, which comprises the administration of a compound of the invention.
- the compounds of the present invention may also be used in combination with other therapeutic or diagnostic agents.
- the compounds of this invention may be coadministered along with other compounds typically prescribed for these conditions according to generally accepted medical practice such as anticoagulant agents, thrombolytic agents, or other antithrombotics, including platelet aggregation inhibitors, tissue plasminogen activators, urokinase, prourokinase, streptokinase, heparin, aspirin, or warfarin.
- the compounds of the present invention may act in a synergistic fashion to prevent reocclusion following a successful thrombolytic therapy and/or reduce the time to reperfusion. These compounds may also allow for reduced doses of the thrombolytic agents to be used and therefore minimize potential hemorrhagic side-effects .
- the compounds of this invention can be utilized in vivo, ordinarily in mammals such as primates, (e.g. humans), sheep, horses, cattle, pigs, dogs, cats, rats and mice, or in vitro.
- the biological properties of the compounds of the present invention can be readily characterized by methods that are well known in the art, for example by the in vitro protease activity assays and in vivo studies to evaluate antithrombotic efficacy, and effects on hemostasis and hematological parameters, such as are illustrated in the examples.
- Diagnostic applications of the compounds of this invention will typically utilize formulations in the form of solutions or suspensions.
- the compounds of this invention may be utilized in compositions such as tablets, capsules or elixirs for oral administration, suppositories, sterile solutions or suspensions or injectable administration, and the like, or incorporated into shaped articles.
- Subjects in need of treatment (typically mammalian) using the compounds of this invention can be administered dosages that will provide optimal efficacy.
- the dose and method of administration will vary from subject to subject and be dependent upon such factors as the type of mammal being treated, its sex, weight, diet, concurrent medication, overall clinical condition, the particular compounds employed, the specific use for which these compounds are employed, and other factors which those skilled in the medical arts will recognize.
- Formulations of the compounds of this invention are prepared for storage or administration by mixing the compound having a desired degree of purity with physiologically acceptable carriers, excipients, stabilizers etc., and may be provided in sustained release or timed release formulations.
- Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co., (A.R. Gennaro edit. 1985).
- Such materials are nontoxic to the recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, acetate and other organic acid salts, antioxidants such as ascorbic acid, low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidinone, amino acids such as glycihe, glutamic acid, aspartic acid, or arginine, monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose or dextrins, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, counterions such as sodium and/or nonionic surfactants such as Tween, Pluronics or polyethyleneglycol.
- buffers such as phosphate, citrate, acetate and other organic acid salts
- antioxidants such
- Dosage formulations of the compounds of this invention to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile membranes such as 0.2 micron membranes, or by other conventional methods. Formulations typically will be stored in lyophilized form or as an aqueous solution.
- the pH of the preparations of this invention typically will be 3-11, more preferably 5-9 and most preferably 7-8. It will be understood that use of certain of the foregoing excipients. carriers, or stabilizers will result in the formation of cyclic polypeptide salts.
- While the preferred route of administration is by injection, other methods of administration are also anticipated such as orally, intravenously (bolus and/or infusion), subcutaneously, intramuscularly, colonically, rectally, nasally, transdermally or intraperitoneally.
- employing a variety of dosage forms such as suppositories, implanted pellets or small cylinders, aerosols, oral dosage formulations and topical formulations such as ointments, drops and dermal patches.
- the compounds of this invention are desirably incorporated into shaped articles such as implants which may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers commercially available.
- the compounds of the invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
- Liposomes can be formed from a variety of lipids, such as cholesterol, stearylamine or phosphatidylcholines.
- the compounds of this invention may also be delivered by the use of antibodies, antibody fragments, growth factors, hormones, or other targeting moieties, to which the compound molecules are coupled.
- the compounds of this invention may also be coupled with suitable polymers as targetable drug carriers.
- suitable polymers can include polyvinylpyrrolidinone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol.
- compounds of the invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
- Polymers and semipermeable polymer matrices may be formed into shaped articles, such as valves, stents, tubing, prostheses and the like.
- Therapeutic compound liquid formulations generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by hypodermic injection needle.
- Therapeutically effective dosages may be determined by either in vitro or in vivo methods. For each particular compound of the present invention, individual determinations may be made to determine the optimal dosage required.
- the range of therapeutically effective dosages will be influenced by the route of administration, the therapeutic objectives and the condition of the patient. For injection by hypodermic needle, it may be assumed the dosage is delivered into the body's fluids. For other routes of administration, the absorption efficiency must be individually determined for each compound by methods well known in pharmacology. Accordingly, it may be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect.
- the determination of effective dosage levels that is, the dosage levels necessary to achieve the desired result, will be readily determined by one skilled in the art.
- the compounds of the invention can be administered orally or parenterally in an effective amount within the dosage range of about 0.1 to 100 mg/kg, preferably about 0.5 to 50 mg/kg and more preferably about 1 to 20 mg/kg on a regimen in a single or 2 to 4 divided daily doses and/or continuous infusion.
- a compound or mixture of compounds of this invention is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, dye, flavor etc., as called for by accepted pharmaceutical practice.
- a physiologically acceptable vehicle carrier, excipient, binder, preservative, stabilizer, dye, flavor etc.
- the amount of active ingredient in these compositions is such that a suitable dosage in the range indicated is obtained.
- Typical adjuvants which may be incorporated into tablets, capsules and the like are binders such as acacia, corn starch or gelatin, and excipients such as microcrystalline cellulose, disintegrating agents like corn starch or alginic acid, lubricants such as magnesium stearate, sweetening agents such as sucrose or lactose, or flavoring agents.
- a dosage form is a capsule, in addition to the above materials it may also contain liquid carriers such as water, saline, or a fatty oil. Other materials of various types may be used as coatings or as modifiers of the physical form of the dosage unit.
- Sterile compositions for injection can be formulated according to conventional pharmaceutical practice. For example, dissolution or suspension of the active compound in a vehicle such as an oil or a synthetic fatty vehicle like ethyl oleate, or into a liposome may be desired. Buffers, preservatives, antioxidants and the like can be incorporated according to accepted pharmaceutical practice.
- the compounds of the present invention may be synthesized by either solid or liquid phase methods described and referenced in standard textbooks, or by a combination of both methods. These methods are well known in the art. See, Bodanszky, "The Principles of Peptide Synthesis", Hafner, et al, Eds., Springer-Verlag, Berlin. 1984. Starting materials used in any of these methods are commercially available from chemical vendors such as Aldrich, Sigma, Nova Biochemicals, Bachem Biosciences, and the like, or may be readily synthesized by known procedures.
- Reactions are carried out in standard laboratory glassware and reaction vessels under reaction conditions of standard temperature and pressure, except where otherwise indicated.
- reaction products are isolated and purified by conventional methods, typically by solvent extraction into a compatible solvent.
- the products may be further purified by column chromatography or other appropriate methods.
- the peptide derivatives can be prepared by sequence coupling of protected Fragment-
- Fragment-2 can be first coupled to Fragment- 1 to yield an intermediate to which Fragment-3 can then be coupled (Scheme II).
- the protecting groups are finally removed by HF-cleavage.
- corhpounds are purified by reversed-phase HPLC and characterized by ion- spray MS spectrometry.
- P is a protecting group
- P is a protecting group
- the "D" substituent illustrated in Fragment- 1 is -CO-. Fragments similar to the structure of Fragment-1, where D is -SO , -CH 2 -, -O-CO-, -NR 15 SO 2 - or -NR 15 -CO-, can easily be synthesized by techniques such as those described in Semple, et al. , WO 95/35311.
- R 1 and R 2 " substituents illustrated in Fragment-2 are -H. Fragments similar to the structure of Fragment-2, where R 1 is C
- the "Y" substituent illustrated in Fragment-3 is -CO-G, where G is:
- R 9 and R 10 are H. Fragments similar to the structure of Fragment-3, where G is: and J is -SO- or -SO 2 - can easily be synthesized by techniques that are well known in the art. Fragments where J is -O- can be synthesized by techniques illustrated in J. Am. Chem. Soc. 1 14: 1854-1863 (1992), J. Med. Chem. 38:76-85 (1995), and J. Med. Chem. 37:3492-3502 (1994). Lastly, fragments where J is -NR*-, where R is H, C,. 6 alkyl or benzyl, can be synthesized by techniques illustrated in J. Med. Chem. 37:3492-3502 (1994). All of these references are inco ⁇ orated herein by reference. Fragments similar to the structure of Fragment-3, where G is:
- R 7 , R 8 , R 9 and R 10 are not H, can also be easily synthesized by techniques that are well known in the art.
- Fragments similar to the structure of Fragment-3, where G is -COOR 20 , -CONR :0 R 21 , -CF 3 or -CF 2 CF 3 , can easily be synthesized by techniques that are well known in the art.
- Fragments similar to the structure of Fragment-3. where "Y" is a boron-containing group can easily be synthesized by techniques that are well known in the art. See for example, J. Org. Chem. 60:3717-3722 ( 1995). The mechanisms for coupling the various fragments used to synthesize the compounds of the instant invention, are also well known in the art.
- N- ⁇ -Boc-N- ⁇ -CBZ-L-ornithine (10 g, 0.027 mol) is dissolved in a solution of MeOH
- TLC showed clean conversion to N- ⁇ -Boc-L-ornithine.
- the crude intermediate is dissolved in dry DMF (60 mL) and heated to 50-60°C for 2.5 hours. The solvent is removed under vacuum. The oil residue is dissolved in 50 mL of CH 2 C1 2 and extracted with 50 mL of 1 N NaOH. The aqueous solution is extracted with 50 mL of CH 2 C1 2 , acidified with cooling with 50 mL of IN HCl, re-extracted with 5
- Example 3 The compounds of Example 3 ( 1 mmol) and Example 4 ( 1 mmol) are dissolved in DMF (5 mL) and cooled to 0°C. The solution is neutralized with DIEA ( 1 mL) followed by addition of coupling reagent BOP (1.1 mmol). The solution is stirred for 1-2 hours and HPLC analysis showed the completion of reaction. Solvent is removed by vacuum at 30°C. The residue is dissolved in a mixture of EtOAc-H 2 0 (50 mL: 10 mL). The organic layer is washed with sat. NaHCO 3 (2 X 10 mL), sat. NaCl (2 X 10 mL), dried over MgS0 4 , filtered and solvent evaporated. The oil residue is purified by flash column on SiO 2 to give the compound shown above, as a powder.
- Example 4 The compound of Example 4 (1 mmol) is dissolved in 1 mL of MeOH, cooled to 0°C and treated dropwise with sat. HCl in MeOH (4 mL). The solution is stirred at 0°C for 1 hour and then warmed to room temperature and stirred for 14 hours. The solution is concentrated under vacuum to afford the compound shown above, as a clear oil which is used directly in the next example.
- Example 9 The compounds of Example 9 (1 mmol) and 4-(Di-CBZ-guanidine)-butano ⁇ c acid (1 mmol) are dissolved in DMF (5 mL) and cooled to 0°C. The solution is neutralized with DIEA (1 mL) followed by addition of coupling reagent BOP (1.1 mmol). The solution is stirred for 1-2 hours and HPLC analysis showed the completion of reaction. Solvent is removed by vacuum at 30°C. The residue is dissolved in a mixture of EtOAc-H 2 0 (50 mL: 10 mL) and aqueous layer is discarded. The organic layer is washed with sat. NaHCO 3 (2 X 10 mL), sat. NaCl (2 X 10 mL), dried over MgSO 4 , filtered and evaporated. The oil residue is purified by flash column on SiO 2 to give the compound shown above, as a powder.
- Example 10 The compound of Example 10 (1 mmol) is dissolved in MeOH (1 mL) and cooled to 0°C. 5 mL of 1 N LiOH is added dropwise to the mixture and the solution is stirred at
- Example 1 1 (1 mmol) and Example 3 (1 mmol) are dissolved in DMF (5 mL) and cooled to 0°C.
- the solution is neutralized with DIEA ( 1 mL) followed by the addition of coupling reagent BOP (1.1 mmol).
- the solution is stirred for 1-2 hours and HPLC analysis shows the completion of reaction.
- Solvent is removed by vacuum at 30°C.
- the residue is dissolved in a mixture of EtOAc-H 2 O (50 mL: 10 mL) and aqueous layer is discarded.
- the organic layer is washed with sat. NaHCO 3 (2 X 10 mL), sat. NaCl (2 X 10 mL), dried over MgSO , filtered and evaporated.
- the oil residue is purified by flash column on SiO 2 to give the compound shown above, as a powder.
- EXAMPLE 14 (Determination of ICso) The compounds of the present invention are first dissolved in a buffer to give solutions containing concentrations such that assay concentrations range from 0-100 ⁇ M.
- a synthetic chromogenic substrate In assays for thrombin, prothrombinase and factor Xa, a synthetic chromogenic substrate would be added to a solution containing a test compound and the enzyme of interest and the residual catalytic activity of that enzyme would then be determined spectrophotometrically.
- the IC50 of a compound is determined from the substrate turnover.
- the IC 50 is the concentration of test compound giving 50% inhibition of the substrate turnover.
- Preferred compounds of the invention desirably have an IC 50 of less than 500 nM in the factor Xa assay, preferably less than 200 nM, and more preferably less than 100 nM.
- Preferred compounds of the invention desirably have an IC 50 of less than 4.0 ⁇ M in the prothrombinase assay, preferably less than 200 nM, and more preferably less than 10 nM.
- Preferred compounds of the invention desirably have an IC 50 of greater than 1.0 ⁇ M in the thrombin assay, preferably greater than 10.0 ⁇ M, and more preferably greater than 100.0 ⁇ M.
- Amidolytic Assays for determining protease inhibition activity Factor Xa and thrombin assays are performed at room temperature, in 0.02 M Tris HCl buffer, pH 7.5, containing 0.15 M NaCl.
- the rates of hydrolysis of the para- nitroanilide substrate S-2765 (Chromogenix) for factor Xa, and the substrate Chromozym TH (Boehringer Mannheim) for thrombin following preincubation of the enzyme with the test compound for 5 minutes at room temperature are determined using a Softmax 96-well plate reader (Molecular Devices), monitored at 405 nm to measure the time dependent appearance of p-nitroanilide.
- prothrombinase inhibition assay is performed in a plasma free system with modifications to the method as described by Sinha, et al., Thromb. Res., 75:427-436
- the activity of the prothrombinase complex is determined by measuring the time course of thrombin generation using the p-nitroanilide substrate Chromozym TH.
- the assay consists of a 5 minute preincubation of selected compounds to be tested as inhibitors with the complex formed from factor Xa (0.5 nM), factor Va (2 nM), phosphatidyl serine:phosphatidyl choline (25:75, 20 ⁇ M) in 20 mM Tris HCl buffer, pH
- the antithrombotic efficacy of the compounds of this invention can readily be evaluated using a series of studies in rabbits, as described below. These studies are also useful in evaluating a compounds effects on hemostasis and its the hematological parameters. Antithrombotic Efficacy in a Rabbit Model of Venous Thrombosis
- Rabbits are anesthetized with I.M. injections of Ketamine, Xylazine, and Acepromazine cocktail.
- a standardized protocol consists of insertion of a thrombogenic cotton thread and copper wire apparatus into the abdominal vena cava of the anesthetized rabbit.
- a non- occlusive thrombus is allowed to develop in the central venous circulation and inhibition of thrombus growth is then used as a measure of the antithrombotic activity of the compound being evaluated.
- Test agents or control saline are administered through a marginal ear vein catheter.
- a femoral vein catheter is used for blood sampling prior to and during steady state infusion of the compound being evaluated. Initiation of thrombus formation will begin immediately after advancement of the cotton thread apparatus into the central venous circulation.
- the rabbits are euthanized and the thrombus excised by surgical dissection and characterized by weight and histology. Blood samples are then analyzed for changes in hematological and coagulation parameters.
Abstract
L'invention concerne de nouveaux composés, leurs sels et des compositions relatives auxdits composés ayant une activité contre le facteur mammifère Xa. Lesdits composés sont utiles in vitro ou in vivo pour la prévention ou le traitement de troubles de la coagulation.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP51845498A JP2001504810A (ja) | 1996-10-11 | 1997-10-10 | 選択的第Xa因子阻害剤 |
CA002268281A CA2268281A1 (fr) | 1996-10-11 | 1997-10-10 | Inhibiteurs competitifs du facteur xa |
AU49809/97A AU720513C (en) | 1996-10-11 | 1997-10-10 | Selective factor Xa inhibitors |
EP97912697A EP0937073A2 (fr) | 1996-10-11 | 1997-10-10 | Inhibiteurs competitifs du facteur xa |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3374996P | 1996-10-11 | 1996-10-11 | |
US73136696A | 1996-10-11 | 1996-10-11 | |
US60/033,749 | 1996-10-11 | ||
US08/731,366 | 1996-10-11 | ||
US08/948,672 US6262047B1 (en) | 1996-10-11 | 1997-10-10 | Selective factor Xa inhibitors |
US08/948,672 | 1997-10-10 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1998016523A2 WO1998016523A2 (fr) | 1998-04-23 |
WO1998016523A3 WO1998016523A3 (fr) | 1998-06-18 |
WO1998016523A9 true WO1998016523A9 (fr) | 1998-08-27 |
Family
ID=27364485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/018291 WO1998016523A2 (fr) | 1996-10-11 | 1997-10-10 | Inhibiteurs competitifs du facteur xa |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0937073A2 (fr) |
JP (1) | JP2001504810A (fr) |
CA (1) | CA2268281A1 (fr) |
WO (1) | WO1998016523A2 (fr) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6194435B1 (en) | 1996-10-11 | 2001-02-27 | Cor Therapeutics, Inc. | Lactams as selective factor Xa inhibitors |
US6063794A (en) | 1996-10-11 | 2000-05-16 | Cor Therapeutics Inc. | Selective factor Xa inhibitors |
US6369080B2 (en) | 1996-10-11 | 2002-04-09 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
US6262047B1 (en) | 1996-10-11 | 2001-07-17 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
EP0977772A1 (fr) | 1997-04-14 | 2000-02-09 | Cor Therapeutics, Inc. | INHIBITEURS SELECTIFS DU FACTEUR Xa |
AU747531B2 (en) | 1997-04-14 | 2002-05-16 | Millennium Pharmaceuticals, Inc. | Selective factor Xa inhibitors |
US6133256A (en) * | 1997-04-14 | 2000-10-17 | Cor Therapeutics Inc | Selective factor Xa inhibitors |
NZ500352A (en) | 1997-04-14 | 2001-10-26 | Cor Therapeutics Inc | Cyclic diaza selective factor Xa inhibitors |
US6218382B1 (en) | 1997-08-11 | 2001-04-17 | Cor Therapeutics, Inc | Selective factor Xa inhibitors |
US6333321B1 (en) | 1997-08-11 | 2001-12-25 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
WO1999007732A1 (fr) * | 1997-08-11 | 1999-02-18 | Cor Therapeutics, Inc. | INHIBITEURS SELECTIFS DU FACTEUR Xa |
NZ502876A (en) * | 1997-08-11 | 2001-11-30 | Cor Therapeutics Inc | Fused bicyclic lactam selective factor Xa inhibitors for treating thrombosis related diseases |
US6228854B1 (en) | 1997-08-11 | 2001-05-08 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
AU753842B2 (en) * | 1997-08-11 | 2002-10-31 | Millennium Pharmaceuticals, Inc. | Selective factor Xa inhibitors |
NZ525513A (en) | 1998-08-07 | 2004-09-24 | Pont Pharmaceuticals Du | Succinoylamino lactams as inhibitors of Abeta protein production |
HRP990246A2 (en) | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
CN1636011A (zh) | 1998-12-24 | 2005-07-06 | 杜邦药品公司 | 作为Aβ蛋白产生抑制剂的琥珀酰氨基苯并二氮杂䓬 |
US6262080B1 (en) | 1998-12-31 | 2001-07-17 | Avantis Pharmaceuticals Inc. | 3-(thio-substitutedamido)-lactams useful as inhibitors of matrix metalloproteinase |
JP2002536437A (ja) * | 1999-02-09 | 2002-10-29 | ブリストル−マイヤーズ スクイブ カンパニー | FXaのラクタム抑制剤および方法 |
US6344450B1 (en) | 1999-02-09 | 2002-02-05 | Bristol-Myers Squibb Company | Lactam compounds and their use as inhibitors of serine proteases and method |
US6297233B1 (en) | 1999-02-09 | 2001-10-02 | Bristol-Myers Squibb Company | Lactam inhibitors of FXa and method |
PT1212300E (pt) * | 1999-09-13 | 2004-03-31 | Dimensional Pharm Inc | Inibidores de serina-protease de azacicloalcanona |
US6960576B2 (en) | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
US6503902B2 (en) | 1999-09-13 | 2003-01-07 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production |
AU7997700A (en) | 1999-10-08 | 2001-04-23 | Du Pont Pharmaceuticals Company | Amino lactam sulfonamides as inhibitors of abeta protein production |
AU2001239791A1 (en) | 2000-02-17 | 2001-08-27 | Du Pont Pharmaceuticals Company | Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production |
US6495540B2 (en) | 2000-03-28 | 2002-12-17 | Bristol - Myers Squibb Pharma Company | Lactams as inhibitors of A-β protein production |
CN1434803A (zh) | 2000-04-03 | 2003-08-06 | 布里斯托尔-迈尔斯斯奎布药品公司 | 作为Aβ蛋白质产生抑制剂的环内酰胺 |
AU2001253090A1 (en) | 2000-04-03 | 2001-10-15 | Bristol-Myers Squibb Pharma Company | Cyclic lactams as inhibitors of abeta protein production |
AU2001257006A1 (en) | 2000-04-11 | 2001-10-23 | Du Pont Pharmaceuticals Company | Substituted lactams as inhibitors of abeta protein production |
BR0106717A (pt) | 2000-06-01 | 2002-04-16 | Bristol Myers Squibb Pharma Co | Compostos, composição farmacêutica e usos dos compostos de lactama inovadora |
US6511973B2 (en) | 2000-08-02 | 2003-01-28 | Bristol-Myers Squibb Co. | Lactam inhibitors of FXa and method |
HUP0304058A2 (hu) | 2001-01-30 | 2004-04-28 | Bristol-Myers Squibb Company | Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
GB0114005D0 (en) | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
GB0114004D0 (en) | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
GB0127568D0 (en) * | 2001-11-16 | 2002-01-09 | Glaxo Group Ltd | Chemical compounds |
SI1569912T1 (sl) | 2002-12-03 | 2015-09-30 | Pharmacyclics Llc | Derivati 2-(2-hidroksibifenil-3-il)-1h-benzoimidazol-5-karboksamidina kot inhibitorji faktorja viia |
GB0228533D0 (en) * | 2002-12-06 | 2003-01-15 | Glaxo Group Ltd | Crystalline form |
SG176628A1 (en) | 2009-06-05 | 2012-01-30 | Link Medicine Corp | Aminopyrrolidinone derivatives and uses thereof |
US11091447B2 (en) | 2020-01-03 | 2021-08-17 | Berg Llc | UBE2K modulators and methods for their use |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL119466A (en) * | 1995-11-03 | 2001-08-26 | Akzo Nobel Nv | Thrombin inhibitors, their preparation and pharmaceutical compositions containing them |
CA2246256A1 (fr) * | 1996-02-13 | 1997-08-21 | Akzo Nobel Nv | Inhibiteurs de la serine protease |
-
1997
- 1997-10-10 WO PCT/US1997/018291 patent/WO1998016523A2/fr not_active Application Discontinuation
- 1997-10-10 JP JP51845498A patent/JP2001504810A/ja active Pending
- 1997-10-10 CA CA002268281A patent/CA2268281A1/fr not_active Abandoned
- 1997-10-10 EP EP97912697A patent/EP0937073A2/fr not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998016523A9 (fr) | Inhibiteurs competitifs du facteur xa | |
EP0937073A2 (fr) | Inhibiteurs competitifs du facteur xa | |
AU4898897A (en) | Selective factor xa inhibitors | |
WO1999007732A1 (fr) | INHIBITEURS SELECTIFS DU FACTEUR Xa | |
EP0994894A1 (fr) | INHIBITEURS SELECTIFS DU FACTEUR Xa | |
AU743544B2 (en) | Selective factor Xa inhibitors | |
US6204268B1 (en) | Selective factor Xa inhibitors | |
US6262047B1 (en) | Selective factor Xa inhibitors | |
EP0994893B1 (fr) | INHIBITEURS SELECTIFS DU FACTEUR Xa CONTENANT UNE STRUCTURE D'AZEPINONE CONDENSEE | |
AU741099B2 (en) | Selective factor Xa inhibitors | |
US6369063B1 (en) | Selective factor Xa inhibitors | |
WO1998046591A1 (fr) | INHIBITEURS SELECTIFS DU FACTEUR Xa | |
US6525076B1 (en) | Selective factor Xa inhibitors | |
US6333321B1 (en) | Selective factor Xa inhibitors | |
US6228854B1 (en) | Selective factor Xa inhibitors | |
US6369080B2 (en) | Selective factor Xa inhibitors | |
US6194435B1 (en) | Lactams as selective factor Xa inhibitors | |
WO1998016524A1 (fr) | DERIVES HETEROCYCLIQUES UTILISES COMME INHIBITEURS DE FACTEUR Xa | |
AU720513C (en) | Selective factor Xa inhibitors | |
US6218382B1 (en) | Selective factor Xa inhibitors | |
AU746596B2 (en) | Selective factor Xa inhibitors | |
AU743614B2 (en) | Heterocyclic derivatives as factor Xa inhibitors | |
AU8826998A (en) | Selective factor xa inhibitors containing a fused azepinone structure | |
AU8700598A (en) | Selective factor xa inhibitors |